A prospective randomized administration of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 2, 1997, Pages 202-208

  Ikeda, Kenji ^a   Saitoh, Satoshi ^b   Suzuki, Yoshiyuki ^b   Koida, Isao ^b   Tsubota, Akihito ^b   Kobayashi, Masahiro ^b   Arase, Yasuji ^b   Chayama, Kazuaki ^b   Murashima, Naoya ^b   Kumada, Hiromitsu ^b  

^a TORANOMON HOSPITAL   (Japan)

^b NONE

Author keywords

5' Deoxy 5 fluorouridine; Adjuvant chemotherapy; Hepatocellolar carcinoma; Transcatheter arterial embolization

Indexed keywords

DOXIFLURIDINE; DOXORUBICIN; MITOMYCIN C;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUMOR NECROSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; FEMALE; FLOXURIDINE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030940164     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199704000-00021     Document Type: Article

References (40)

1. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer 1987;60:1400-11.
2. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan: Clinicopathological features and results of surgical treatment. Ann Surg 1990;211:277-87.
3. Wheeler PG, Melia W, Dubbins P, et al. Non-operative arterial embolization in primary liver tumours. Br Med J 1979;2:242-4.
4. Chuang VP, Wallace S. Hepatic arterial embolization in the treatment of hepatic neoplasms. Radiology 1981;140:51-8.
5. Okamura J, Horikawa S, Fujiyama T, et al. An appraisal of transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies. World J Surg 1982;6:352-7.
6. Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401.
7. Lin DY Liaw YF, Lee TY, et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Gastroenterology 1988;94:453-6.
8. Ikeda K, Oyake E, Kumada H, et al. Evaluation of transcatheter arterial embolization therapy for hepatocellular carcinoma [English abstract]. Nippon Shokakibyo Gakkai Zasshi 1984; 81:249-53.
9. Sakurai M, Okamura J, Kuroda C. Transcatheter chemoembolization effective for treatment for treating hepatocellular carcinoma: A histopathological study. Cancer 1984;54:387-92.
10. Wakasa K, Sakurai M, Kuroda C, et al. Effect of transcatheter arterial embolization on the boundary architecture of hepato-cellular carcinoma. Cancer 1990;65:913-9.
11. Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 1991;68:2150-4.
12. Geddes EW, Falkson G. Malignant hepatoma in the Bantu. Cancer 1970;25:1271-8.
13. Davis HL, Ramirez G, Ansfield FJ. Adenocarcinoma of stomach pancreas, and liver and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 1974;33: 195-208.
14. Cady B, Oberfeld RA. Arterial infusion chemotherapy of hepatoma. Surg Gynecol Obstet 1974;138:381-4.
15. Ansfield FJ, Ramirez G, Davis HL, et al. Further clinical studies with intrahepatic artery infusion with 5-fluorouracil. Cancer 1975;36:2413-7.
16. Sullivan RD. Systemic and arterial infusion chemotherapy for metastatic liver cancer. Int J Radiat Oncol Biol Phys 1976;1: 975-6.
17. Misawa S, Ookuma S, Ide T, et al. Cancer chemotherapy with futraful suppository for inoperable gastrointestinal cancer -clinical effects with single and combined therapy [English abstract]. J Jpn Soc Cancer Ther 1976;11:535-45.
18. Link JS, Bateman JR, Paroly WS, et al. 5-Fluorouracil in hepatocellular carcinoma: Report of twenty-one cases. Cancer 1977;39:1936-9.
19. Pettavel J, Morgethales F. Protracted arterial chemotherapy of liver tumors: An experience of 107 cases - over a 12-year period. Prog Clin Cancer 1978;7:217-33.
20. Falkson G, Moertel CG, Lavin P, et al. Chemotherapy studies in primary liver cancer: A prospective randomized clinical trial. Cancer 1978;42:2149-56.
21. Tokyo Liver Cancer Chemotherapy Study Group. Phase II study of coadministration of uracil and tegafur (UFT) in hepatocellular carcinoma. Jpn J Clin Oncol 1985;15:559-62.
22. Kitamura T, Maruyama T, Nakamura H, et al. Therapy for hepatocellular carcinoma with UFT - clinical evaluation of its effect in the combination therapy with transcatheter arterial embolization or one shot therapy [English abstract]. Jpn J Cancer Chemother 1990;17(part 1):1467-71.
23. Ikeda K, Kumada H, Arase Y, et al. Effects and side effects of long-term administration of oral antitumor agents for patients with hepatocellular carcinoma - especially, relation to aggravation of liver function [English abstract]. Nippon Shokakibyo Gakkai Zasshi 1987;84:2377-85.
24. Ikeda K, Kumada H, Arase Y, et al. Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma with liver cirrhosis - relationship with serum concentration of anti-tumor agents and side effect [English abstract]. Nippon Shokakibyo Gakkai Zasshi 1988;85:2411-9.
25. Ikeda K, Saitoh S, Koida I, et al. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995;18:204-10.
26. Cook AF, Holman MJ, Kramer MJ, et al. Fluorinated pyrimidine nucleotides. 3. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 1979;22:1330-5.
27. Armstrong RD, Diasio RB. Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res 1980;40:3333-8.
28. Ishitsuka H, Miwa M, Takemoto K, et al. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980;71:112-23.
29. Au JL-S, Rustum YM, Minowada J, et al. Differential selectivity of 5-fluorouracil and 5′-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia. Biochem Pharmacol 1983;32:541-6.
30. Kono A, Hara Y, Sugita S, et al. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 1983;31:175-8.
31. Ohta Y, Sueki K, Kitta K, et al. Comparative studies on the immunosuppressive effect among 5′-deoxy-5-fluorouridine, florafur, and 5-fluorouracil. Gann 1980;71:190-6.
32. Bollag W, Hartman HR. Tumor inhibitory effects of a new fluorouracil derivative: 5′-Deoxy-5-fluorouridine. Eur J Cancer 1980;16:427-32.
33. Connolly KM, Diasio RB, Armstrong RD, et al. Decreased immunosuppression associated with anti-tumor activity of 5′-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine. Cancer Res 1983;43:2529-35.
34. Uehara N, Baba H, Nitta K, et al. The therapeutic effects of orally administered 5′-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors. Jpn J Cancer Res (Gann) 1985;76:1034-41.
35. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
36. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:248-75.
37. Dixon WJ, Brown MB, Engleman L, et al. BMDP statistical software. Berkeley: University of California Press, 1985.
38. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepato-cellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
39. Tanaka Y, Eda H, Fujimoto K, et al. Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 1990;50:4528-32.
40. Ishikawa T, Tanaka Y, Ishitsuka H, et al. Comparative antitumor activity of 5′-deoxy-5-fluorouridine in combination with radiation with radiation therapy in mice bearing colon 26 adenocarcinoma. Jpn J Cancer Res 1989;80:583-91.